Clinical Trials Logo

Clinical Trial Summary

Familial hypercholesterolaemia (FH) is a genetic disorder characterised by elevated plasma LDLC levels. The causal role of low-density lipoprotein cholesterol (LDLC) in the progression of cardiovascular disease (CVD) is indisputable: genetic, epidemiological and interventional trials have unanimously shown that a reduction in LDL-C is associated with a reduced risk of CVD. Some drawbacks related to the limitations of the analytical methods are slowly surfacing due to the lower LDLC target achieved with the combination of several new treatments. This is mainly due to the fact that LDLC is not a comprehensive marker to stratify cardiovascular risk in subjects with increased levels of other atherogenic lipoproteins. Direct measurement of the concentration of apolipoproteins involved in cholesterol and triglycerides transportation, may provide more information than the simple measure of the cholesterol contained in these particles. There is an interest in measuring the various players involved in the lipoprotein processing chain. These apolipoproteins are increasingly being considered as possible biomarkers of cardiovascular disease risk. Indeed, there is increasing evidence that advanced lipoprotein testing methods, such as multiplexed measurements of apolipoprotein panels (ApoA-I, A-II, A-IV, B-100, C-I, C-II, C-III, E), provide more detailed information on the dyslipidaemic profiles of patients compared to conventional lipid testing, finally allowing a better understanding and stratification of subclinical atherosclerosis in these patients. The main objective of this study is to compare the apolipoprotein profile of patients with FH by comparing those with associated hypertriglyceridemia (hyperTG) to those with isolated hypercholesterolaemia. Adult subjects with a molecular diagnosis of Familial Hypercholesterolemia, treated by a statin, on primary prevention, asymptomatic for cardiovascular symptoms, will be recruited and stratified according to the presence/absence of hyperTG in a case-control prospective observational study design.


Clinical Trial Description

The crucial role of dyslipidaemia, in particular hypercholesterolaemia, in the development of cardiovascular diseases is particularly well documented. The causal role of LDLC in the progression of CVD is indisputable: genetic, epidemiological and interventional trials have unanimously shown that a reduction in LDL-C is associated with a reduced risk of CVD. Some drawbacks related to the limitations of the analytical methods are slowly surfacing due to the lower LDLC target achieved with the combination of several new treatments. This is mainly due to the fact that LDLC is not a comprehensive marker to stratify cardiovascular risk in subjects with increased levels of other atherogenic lipoproteins. Familial hypercholesterolaemia (FH) is a genetic disorder characterised by elevated plasma LDLC levels. Plasma levels of key lipoproteins, including LDLC levels, are major determinants and triggers of vascular endothelial damage; monocyte to macrophage differentiation and foam cell formation, leading to the development of atherosclerotic lesions; premature coronary artery disease (CAD); peripheral arterial disease; and supra-aortic stenosis. The earlier these events occur, the higher the cholesterol level. A growing body of experimental and clinical evidence suggests that triglyceride-rich lipoproteins (TRL), and in particular remnant particles, contribute to atherogenesis and thus to the progression of cardiovascular disease. In addition, these lipids such as cholesterol and triglycerides (TG) circulate in blood plasma as lipoproteins, supramolecular assemblies whose structure is provided by specific proteins: apolipoproteins. Direct measurement of the concentration of atherogenic particles involved in the metabolism of cholesterol and TG could therefore provide more information than simply measuring the cholesterol contained in these particles. There is an interest in measuring the various players involved in the lipoprotein processing chain. These apolipoproteins are increasingly being considered as possible biomarkers of cardiovascular disease risk. Indeed, there is increasing evidence that advanced lipoprotein testing methods, such as multiplexed measurements of apolipoprotein panels (ApoA-I, A-II, A-IV, B-100, C-I, C-II, C-III, E), provide more detailed information on the dyslipidaemic profiles of patients compared to conventional lipid testing, allowing for a better understanding and stratification of subclinical atherosclerosis in these patients. Primary objective: To compare the apolipoprotein profile of patients with FH by comparing those with associated hyperTG to those with isolated hypercholesterolaemia. Secondary objectives: Compare the subclinical impairment of FH patients with and without hyperTG - Compare the coronary atherosclerotic burden, assessed by the Calcium Score - Compare carotid atherosclerotic burden, assessed by echodoppler - Compare femoral atherosclerotic burden, assessed by echodoppler Conduct of the research : The patient will be informed of the study and if agree to participate, additional blood tubes will be collected for the research during the blood sampling carried out as part of the usual care. Analysis will be performed in collaboration with LNE, the France's national metrology laboratory as part of the European CARDIOMET project. A biobank and serum library will also be constituted during the study for further and additional analysis. Two groups of patients will be enrolled : - patients with familial hypercholesterolaemia (FH) and hypertriglyceridemia (hyperTG) - patients with familial hypercholesterolaemia (FH) without hypertriglyceridemia (hyperTG) ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05066932
Study type Observational
Source Assistance Publique - Hôpitaux de Paris
Contact Eric BRUCKERT
Phone 01 42 17 57 84
Email [email protected]
Status Not yet recruiting
Phase
Start date October 2021
Completion date October 2022

See also
  Status Clinical Trial Phase
Recruiting NCT05052918 - The Effect of Exercise and Metformin on Carotid Intima-media Thickness in Patients With Prediabetes N/A
Recruiting NCT04511234 - Sirolimus Coated Balloon Versus Standard Balloon for SFA and Popliteal Artery Disease N/A
Completed NCT03273972 - INvestigating the Lowest Threshold of Vascular bENefits From LDL Lowering With a PCSK9 InhibiTor in healthY Volunteers N/A
Recruiting NCT02932176 - Machine Learning for Handheld Vascular Studies
Completed NCT01212900 - Randomized Trial of Imaging Versus Risk Factor-Based Therapy for Plaque Regression Phase 4
Completed NCT03697382 - Effect of Daily Steps on Fat Metabolism N/A
Completed NCT03654313 - Single and Multiple Ascending Doses of MEDI6570 in Subjects With Type 2 Diabetes Mellitus Phase 1
Completed NCT00382564 - Magnetic Resonance Angiography to Diagnose Atherosclerotic Disease N/A
Recruiting NCT02998918 - Effects of Short-term Curcumin and Multi-polyphenol Supplementation on the Anti-inflammatory Properties of HDL Phase 2
Recruiting NCT02894931 - Effects of Dietary Interventions on Serum and Macrophage Atherogenicity N/A
Not yet recruiting NCT02578355 - National Plaque Registry and Database N/A
Recruiting NCT02265250 - Pilot Study-Magnetic Resonance Imaging for Global Atherosclerosis Risk Assessment
Completed NCT02268513 - Mediators of Atherosclerosis in South Asians Living in America (MASALA) Social Network Study
Completed NCT02224339 - New Technologies to Determine Carotid Plaque Vulnerability
Completed NCT03393377 - Preventive Arterial Wall Phenotype and Low-dose Fluvastatin/Valsartan Combination N/A
Not yet recruiting NCT01923012 - Phase II Randomized Placebo-controlled Study With Vitamin K2 in Asymptomatic Calcified Carotid Stenosis Phase 2
Completed NCT02377310 - Pd/Pa vs iFRâ„¢ in an Unselected Population Referred for Invasive Angiography N/A
Completed NCT02116829 - Is There Room for Butter in a Healthy Diet? N/A
Recruiting NCT02124928 - Morphological and Serological Criteria of Plaque Vulnerability: Risk Assessment for Symptomatic and Asymptomatic Carotid Artery Stenosis N/A
Not yet recruiting NCT01653600 - Efficacy of Self-Expanding Nitinol S.M.A.R.T CONTROL Stent Versus Life Stent For The Atherosclerotic Femoro-Popliteal Arterial Disease Phase 4